← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Rezafungin

FDA approved · Rx

Echinocandin antifungal

Also known as: Rezzayo, Rezafungin ion, Rezafungin cation, Biafungin, CD101, CD-101, SP-3025, REZZAYO

Evidence score
91/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 11 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Rezafungin is a semisynthetic cyclic lipopeptide antifungal in the echinocandin class, sold under the brand name Rezzayo. Like other echinocandins, it blocks the enzyme 1,3-beta-D-glucan synthase, which fungi need to build their cell walls. It was designed for greater stability and a long half-life, allowing less frequent intravenous administration than older drugs in its class.

What the evidence shows

Automatic summaryHuman trials

Rezafungin is FDA approved for treating candidemia and invasive candidiasis in adults with limited or no alternative treatment options, based on human clinical trials including phase 3 data. Its use for other purposes, such as preventing fungal infections, is still being studied and is not established.

Key facts

Molecular formula
C63H85N8O17+
Molecular weight
1226.4 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

11registered studies
Phase 4most advanced phase
3completed (sample)
1recruiting (sample)

Rezafungin Prophylaxis in Liver Transplant

Phase 3Enrolling By InvitationNCT06774144

Rezafungin Pharmacokinetics in Patients on ECMO

Phase 1WithdrawnNCT06329518

Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal Candidiasis

Phase 4Active Not RecruitingNCT06985758

Rezafungin Peritoneal Diffusion for Intra-abdominal Candidiasis

CompletedNCT07093203

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

255papers referencing Rezafungin

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.

Drugs2021

Echinocandins - structure, mechanism of action and use in antifungal therapy.

J Enzyme Inhib Med Chem2022

Aspiring Antifungals: Review of Current Antifungal Pipeline Developments.

J Fungi (Basel)2020

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.

Lancet2023

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.